A Study to Compare Two vs. Three Antibiotic Therapies for Pulmonary Mycobacterium Avium Complex Disease


About this study

The purpose of this study is to determine whether 2-drug therapy is non-inferior to 3-drug therapy against pulmonary mycobacterium avium complex (MAC) disease, and whether 2-drug therapy is better tolerated than 3-drug therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Culture positive mcobacterium avium complex (MAC) disease meeting ATS/IDSA case criteria.
  • No prior multi-drug antimicrobial therapy for NTM.
  • Adult males and females.
  • Ability to provide informed consent.

Exclusion Criteria:

  • Fibrocavitary disease.
  • Cystic fibrosis.
  • HIV.
  • History of solid organ or hematologic transplant.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Timothy Aksamit, M.D.

Open for enrollment

Contact information:

Pulmonary Research Study Coordinator

(800) 753-1606

More information


Publications are currently not available

Mayo Clinic Footer